Thermo Scientific MAS Omni IMMUNE and Omni IMMUNE PRO; Liquid Assayed Integrated Immunoassay Con...
FDA Device Recall #Z-0379-2013 — Class III — August 20, 2012
Recall Summary
| Recall Number | Z-0379-2013 |
| Classification | Class III — Low risk |
| Date Initiated | August 20, 2012 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Microgenics Corporation |
| Location | Fremont, CA |
| Product Type | Devices |
| Quantity | 2076 total in US , 596 total Foreign |
Product Description
Thermo Scientific MAS Omni IMMUNE and Omni IMMUNE PRO; Liquid Assayed Integrated Immunoassay Control. Intended for use as an assayed control for monitoring assay conditions in many clinical laboratory determinations. Assay values are provided for the specific systems listed. The user can compare observations with expected ranges as a means of assuring consistent performance or reagent and instrument. .
Reason for Recall
In house testing confirmed that CK-MS and Insulin claimed in both Omni IMMUNE and Omni IMMUNE PRO products are displaying reduced stability.
Distribution Pattern
Worldwide Distribution--USA (nationwide) and the countries of Germany, Canada and Australia.
Lot / Code Information
MAS Onmi IMMUNE: Catalog Number/lot number/ expiration date: OIM-101 - OIM14031 - 31 MAR 2014; OIM-202 - OIM14032 - 31 MAR 2014; OIM-303 - OIM14033 - 31 MAR 2014; OIM-SP - OIM1403S - 31 MAR 2014. MAS Omni IMMUNE PRO: OPRO-101 - OPRO14031 - 31 MAR 2014; OPRO-201 - OPRO14032 - 31 MAR 2014' OPRO-303 - OPRO14033 - 31 MAR 2014; OPRO-SP - OPRO1403S - 31 MAR 2014.
Other Recalls from Microgenics Corporation
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-0415-2026 | Class II | Thermo scientific MAS Omni CARDIO, Liquid Assay... | Oct 1, 2025 |
| Z-1284-2022 | Class II | QMS Tacrolimus Immunoassay REF 10015573 CALIBRA... | Jan 20, 2022 |
| Z-0008-2017 | Class II | Thermo Scientific QMS Everolimus Assay; Model ... | Aug 15, 2016 |
| Z-2884-2016 | Class II | DRI Salicylate Serum Tox Assay, Catalog number ... | Jul 25, 2016 |
| Z-0501-2015 | Class II | MAS CardioImmune XL Cardiac Marker Control; Mo... | Oct 20, 2014 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.